glp-1 agonists weight loss drugs market Size to Hit USD 132.79 Bn by 2035 GLP-1 Agonists Market Report 2025-2033,

Furthermore, slimming preparations are now also being sold as nutritional supplements in addition to illegal weight-loss injections

Looking ahead, the integration of artificial intelligence in nanocarriers design and the development of multifunctional theranostic systems-combining therapy and diagnostics-promise to unlock new frontiers in nutraceutical science

Sermorelin is generally a well tolerated peptide, but it can cause side effects such as injection site reactions such as redness, swelling, or pain

The TRIUMPH 4 study showed that patients with obesity and knee arthritis lost an average of almost 29% of their body weight - an average weight loss of 71 pounds

Patients who experience substantial weight loss or excellent glycemic control with minimal side effects are more likely to continue long-term therapy

This study demonstrated that USF stimulates FASN expression by binding to the E-box at the FASN promoter